Document is current
Any future updates will be listed below
-
Authors
Borgström, Fredrik
Lorentzon, Mattias
Johansson, Helena
Harvey, Nicholas C.
McCloskey, Eugene
Willems, Damon
Knutsson, Douglas
Kanis, John A.
-
Funding
Funding for this research was provided by:
UCB
Amgen
Osteoporosis Research Ltd
- License Information
-
More Information
Article History
Received: 18 March 2024
Accepted: 8 September 2024
First Online: 4 October 2024
Declarations
:
: JAK is a director of Osteoporosis Research Ltd. which develops and maintains FRAX. DW is an employee of UCB Pharma. FB owns stock in Quantify Research, a contract research organisation that have received funding from UCB Pharma and Amgen Inc. for model development. EM reports grants and/or personal fees from Amgen, Fresenius Kabi, ObsEva, Theramex and UCB, all outside the submitted work. HJ declares no conflicts. NH reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Consilient Healthcare, Kyowa Kirin, Theramex and Internis Pharma, all outside the submitted work. DK was an employee of Quantify Research, a contract research organisation that have received funding from UCB Pharma and Amgen Inc. for model development. ML reports personal fees from Amgen, UCB Pharma, Radius Health, Renapharma, Consilient Health, and Meda/Mylan.
